Table of Contents Author Guidelines Submit a Manuscript
Schizophrenia Research and Treatment
Volume 2016, Article ID 6378137, 12 pages
http://dx.doi.org/10.1155/2016/6378137
Review Article

Drug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric Disorders

1Department of Cell Biology & Physiology, School of Medicine, University of North Carolina, 115 Mason Farm Road, Chapel Hill, NC 27599, USA
2Department of Pediatrics, School of Medicine, Duke University, 905 S. LaSalle Street, Durham, NC 27710, USA

Received 15 December 2015; Accepted 24 February 2016

Academic Editor: Luis San

Copyright © 2016 Hyeong-Min Lee and Yuna Kim. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. T. Bianchi, “Non-serotonin anti-depressant actions: direct ion channel modulation by SSRIs and the concept of single agent poly-pharmacy,” Medical Hypotheses, vol. 70, no. 5, pp. 951–956, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. G. Rammes and R. Rupprecht, “Modulation of ligand-gated ion channels by antidepressants and antipsychotics,” Molecular Neurobiology, vol. 35, no. 2, pp. 160–174, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. M. T. Bianchi, “Promiscuous modulation of ion channels by anti-psychotic and anti-dementia medications,” Medical Hypotheses, vol. 74, no. 2, pp. 297–300, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Y. Zhang and X. C. Tang, “Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease,” Trends in Pharmacological Sciences, vol. 27, no. 12, pp. 619–625, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. E. E. Benarroch, “Tissue plasminogen activator: beyond thrombolysis,” Neurology, vol. 69, no. 8, pp. 799–802, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Crosby, K. H. Deane, and C. E. Clarke, “Amantadine in Parkinson's disease,” Cochrane Database of Systematic Reviews, no. 1, Article ID CD003468, 2003. View at Google Scholar · View at Scopus
  7. R. S. Schwab, A. C. England Jr., D. C. Poskanzer, and R. R. Young, “Amantadine in the treatment of Parkinson's disease,” The Journal of the American Medical Association, vol. 208, no. 7, pp. 1168–1170, 1969. View at Publisher · View at Google Scholar · View at Scopus
  8. H. Mitsuya, K. J. Weinhold, P. A. Furman et al., “3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro,” Proceedings of the National Academy of Sciences of the United States of America, vol. 82, no. 20, pp. 7096–7100, 1985. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Sun, S. Eriksson, and L. Wang, “Identification and characterization of mitochondrial factors modulating thymidine kinase 2 activity,” Nucleosides, Nucleotides & Nucleic Acids, vol. 29, no. 4–6, pp. 382–385, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Yarchoan, R. W. Klecker, K. J. Weinhold et al., “Administration of 3′-azido-3′-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex,” The Lancet, vol. 1, no. 8481, pp. 575–580, 1986. View at Google Scholar
  11. R. F. DeBusk, C. J. Pepine, D. B. Glasser, A. Shpilsky, H. DeRiesthal, and M. Sweeney, “Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease,” The American Journal of Cardiology, vol. 93, no. 2, pp. 147–153, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. W. K. Kroeze and B. L. Roth, “Polypharmacological drugs: “magic shotguns” for psychiatric diseases,” in Polypharmacology in Drug Discovery, J.-U. Peters, Ed., pp. 135–148, John Wiley & Sons, Somerset, NJ, USA, 2012. View at Google Scholar
  13. T. T. Ashburn and K. B. Thor, “Drug repositioning: identifying and developing new uses for existing drugs,” Nature Reviews: Drug Discovery, vol. 3, no. 8, pp. 673–683, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. A. L. Hopkins, “Drug discovery: predicting promiscuity,” Nature, vol. 462, no. 7270, pp. 167–168, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Marusina, D. J. Welsch, L. Rose, D. Brock, and N. Bahr, “The CTSA Pharmaceutical Assets Portal—a public-private partnership model for drug repositioning,” Drug Discovery Today: Therapeutic Strategies, vol. 8, no. 3-4, pp. 77–83, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. K. A. O'Connor and B. L. Roth, “Finding new tricks for old drugs: an efficient route for public-sector drug discovery,” Nature Reviews Drug Discovery, vol. 4, no. 12, pp. 1005–1014, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. T. I. Oprea, J. E. Bauman, C. G. Bologa et al., “Drug repurposing from an academic perspective,” Drug Discovery Today. Therapeutic Strategies, vol. 8, no. 3-4, pp. 61–69, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. P. J. Harrison and M. J. Owen, “Genes for schizophrenia? Recent findings and their pathophysiological implications,” The Lancet, vol. 361, no. 9355, pp. 417–419, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. C. M. Lewis, D. F. Levinson, L. H. Wise et al., “Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: schizophrenia,” American Journal of Human Genetics, vol. 73, no. 1, pp. 34–48, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. J. T. Coyle and R. S. Duman, “Finding the intracellular signaling pathways affected by mood disorder treatments,” Neuron, vol. 38, no. 2, pp. 157–160, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. B. L. Roth, D. Sheffler, and S. G. Potkin, “Atypical antipsychotic drug actions: unitary or multiple mechanisms for ‘atypicality’?” Clinical Neuroscience Research, vol. 3, no. 1-2, pp. 108–117, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. V. Setola and B. L. Roth, “Why mice are neither miniature humans nor small rats: a cautionary tale involving 5-hydroxytryptamine-6 serotonin receptor species variants,” Molecular Pharmacology, vol. 64, no. 6, pp. 1277–1278, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. E. Shorter, “Looking backwards: a possible new path for drug discovery in psychopharmacology,” Nature Reviews Drug Discovery, vol. 1, no. 12, pp. 1003–1006, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Carlsson and D. T. Wong, “A note on the discovery of selective serotonin reuptake inhibitors,” Life Sciences, vol. 61, no. 12, p. 1203, 1997. View at Publisher · View at Google Scholar · View at Scopus
  25. D. T. Wong, F. P. Bymaster, and E. A. Engleman, “Prozac (fluoxetine, lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication,” Life Sciences, vol. 57, no. 5, pp. 411–441, 1995. View at Publisher · View at Google Scholar · View at Scopus
  26. H. Hippius, “A historical perspective of clozapine,” The Journal of Clinical Psychiatry, vol. 60, supplement 12, pp. 22–23, 1999. View at Publisher · View at Google Scholar · View at Scopus
  27. P. J. Conn and B. L. Roth, “Opportunities and challenges of psychiatric drug discovery: roles for scientists in academic, industry, and government settings,” Neuropsychopharmacology, vol. 33, no. 9, pp. 2048–2060, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. J. A. Gray and B. L. Roth, “The pipeline and future of drug development in schizophrenia,” Molecular Psychiatry, vol. 12, no. 10, pp. 904–922, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. J. A. Gray and B. L. Roth, “Molecular targets for treating cognitive dysfunction in schizophrenia,” Schizophrenia Bulletin, vol. 33, no. 5, pp. 1100–1119, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Kane, G. Honigfeld, J. Singer, and H. Meltzer, “Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine,” Archives of General Psychiatry, vol. 45, no. 9, pp. 789–796, 1988. View at Publisher · View at Google Scholar · View at Scopus
  31. H. Y. Meltzer, L. Alphs, A. I. Green et al., “Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT),” Archives of General Psychiatry, vol. 60, no. 1, pp. 82–91, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. J. Brea, M. Castro, M. I. Loza et al., “QF2004B, a potential antipsychotic butyrophenone derivative with similar pharmacological properties to clozapine,” Neuropharmacology, vol. 51, no. 2, pp. 251–262, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Anighoro and G. Rastelli, “Enrichment factor analyses on G-protein coupled receptors with known crystal structure,” Journal of Chemical Information and Modeling, vol. 53, no. 4, pp. 739–743, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. E. Gregori-Puigjané and J. Mestres, “A ligand-based approach to mining the chemogenomic space of drugs,” Combinatorial Chemistry & High Throughput Screening, vol. 11, no. 8, pp. 669–676, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. B. Selvam, S. L. Porter, and I. G. Tikhonova, “Addressing selective polypharmacology of antipsychotic drugs targeting the bioaminergic receptors through receptor dynamic conformational ensembles,” Journal of Chemical Information and Modeling, vol. 53, no. 7, pp. 1761–1774, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. I. Vogt and J. Mestres, “Drug-target networks,” Molecular Informatics, vol. 29, no. 1-2, pp. 10–14, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. B. L. Roth and D.-M. Chuang, “Multiple mechanisms of serotonergic signal transduction,” Life Sciences, vol. 41, no. 9, pp. 1051–1064, 1987. View at Publisher · View at Google Scholar · View at Scopus
  38. J. D. Urban, W. P. Clarke, M. von Zastrow et al., “Functional selectivity and classical concepts of quantitative pharmacology,” Journal of Pharmacology and Experimental Therapeutics, vol. 320, no. 1, pp. 1–13, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. J. D. Urban, G. A. Vargas, M. von Zastrow, and R. B. Mailman, “Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways,” Neuropsychopharmacology, vol. 32, no. 1, pp. 67–77, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. J. Jin, B. L. Roth, and S. Frye, “Novel Functionally Selective Ligands of Dopamine D2 Receptors,” US Patent 20,130,137,679, 2013.
  41. J. A. Allen, J. M. Yost, V. Setola et al., “Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 45, pp. 18488–18493, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. X. Chen, M. F. Sassano, L. Zheng et al., “Structure-functional selectivity relationship studies of β-arrestin-biased dopamine D2 receptor agonists,” Journal of Medicinal Chemistry, vol. 55, no. 16, pp. 7141–7153, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. J. A. Allen and B. L. Roth, “Strategies to discover unexpected targets for drugs active at G protein-coupled receptors,” Annual Review of Pharmacology and Toxicology, vol. 51, pp. 117–144, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. R. B. Mailman, “GPCR functional selectivity has therapeutic impact,” Trends in Pharmacological Sciences, vol. 28, no. 8, pp. 390–396, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. P. Coward, S. D. Chan, H. G. Wada, G. M. Humphries, and B. R. Conklin, “Chimeric G proteins allow a high-throughput signaling assay of Gi-coupled receptors,” Analytical Biochemistry, vol. 270, no. 2, pp. 242–248, 1999. View at Publisher · View at Google Scholar
  46. E. Kostenis, M. Waelbroeck, and G. Milligan, “Techniques: promiscuous Gα proteins in basic research and drug discovery,” Trends in Pharmacological Sciences, vol. 26, no. 11, pp. 595–602, 2005. View at Publisher · View at Google Scholar · View at Scopus
  47. T. P. Kenakin, “Ligand detection in the allosteric world,” Journal of Biomolecular Screening, vol. 15, no. 2, pp. 119–130, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. L. T. May, K. Leach, P. M. Sexton, and A. Christopoulos, “Allosteric modulation of G protein-coupled receptors,” Annual Review of Pharmacology and Toxicology, vol. 47, pp. 1–51, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. J. A. Lewis, E. P. Lebois, and C. W. Lindsley, “Allosteric modulation of kinases and GPCRs: design principles and structural diversity,” Current Opinion in Chemical Biology, vol. 12, no. 3, pp. 269–280, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. Z. Fang, C. Grütter, and D. Rauh, “Strategies for the selective regulation of kinases with allosteric modulators: exploiting exclusive structural features,” ACS Chemical Biology, vol. 8, no. 1, pp. 58–70, 2013. View at Publisher · View at Google Scholar · View at Scopus
  51. B. J. Melancon, C. R. Hopkins, M. R. Wood et al., “Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery,” Journal of Medicinal Chemistry, vol. 55, no. 4, pp. 1445–1464, 2012. View at Publisher · View at Google Scholar · View at Scopus
  52. A. Anighoro, J. Bajorath, and G. Rastelli, “Polypharmacology: challenges and opportunities in drug discovery,” Journal of Medicinal Chemistry, vol. 57, no. 19, pp. 7874–7887, 2014. View at Publisher · View at Google Scholar · View at Scopus
  53. T. Arya, C. Kishor, V. Saddanapu, R. Reddi, and A. Addlagatta, “Discovery of a new genetic variant of methionine aminopeptidase from Streptococci with possible post-translational modifications: biochemical and structural characterization,” PLoS ONE, vol. 8, no. 10, Article ID e75207, 2013. View at Publisher · View at Google Scholar · View at Scopus
  54. R. Nisticò, C. Ferraina, V. Marconi et al., “Age-related changes of protein SUMOylation balance in the AβPP Tg2576 mouse model of Alzheimer's disease,” Frontiers in Pharmacology, vol. 5, article 63, 2014. View at Publisher · View at Google Scholar · View at Scopus
  55. A. S. Bassett, S. W. Scherer, and L. M. Brzustowicz, “Copy number variations in schizophrenia: critical review and new perspectives on concepts of genetics and disease,” The American Journal of Psychiatry, vol. 167, no. 8, pp. 899–914, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. H. M. Grayton, C. Fernandes, D. Rujescu, and D. A. Collier, “Copy number variations in neurodevelopmental disorders,” Progress in Neurobiology, vol. 99, no. 1, pp. 81–91, 2012. View at Publisher · View at Google Scholar · View at Scopus
  57. C. N. Henrichsen, E. Chaignat, and A. Reymond, “Copy number variants, diseases and gene expression,” Human Molecular Genetics, vol. 18, no. 1, pp. R1–R8, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. E. H. Cook Jr. and S. W. Scherer, “Copy-number variations associated with neuropsychiatric conditions,” Nature, vol. 455, no. 7215, pp. 919–923, 2008. View at Publisher · View at Google Scholar · View at Scopus
  59. Z. Liu, J. Zhang, and A. Zhang, “Design of multivalent ligand targeting G-protein-coupled receptors,” Current Pharmaceutical Design, vol. 15, no. 6, pp. 682–718, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. R. Morphy and Z. Rankovic, “Designed multiple ligands. An emerging drug discovery paradigm,” Journal of Medicinal Chemistry, vol. 48, no. 21, pp. 6523–6543, 2005. View at Publisher · View at Google Scholar · View at Scopus
  61. C. P. Adams and V. V. Brantner, “Estimating the cost of new drug development: is it really 802 million dollars?” Health Affairs, vol. 25, no. 2, pp. 420–428, 2006. View at Google Scholar
  62. I. M. Kapetanovic, “Computer-aided drug discovery and development (CADDD): in silico-chemico-biological approach,” Chemico-Biological Interactions, vol. 171, no. 2, pp. 165–176, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. M. Pirmohamed, S. James, S. Meakin et al., “Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients,” British Medical Journal, vol. 329, no. 7456, pp. 15–19, 2004. View at Publisher · View at Google Scholar · View at Scopus
  64. R. Shankar, X. Frapaise, and B. Brown, “LEAN drug development in R&D,” Drug Discovery & Development, vol. 9, no. 5, pp. 57–60, 2006. View at Google Scholar
  65. A. Rowan, Of Mice, Models and Men: A Critical Evaluation of Animal Research, State University of New York Press, Albany, NY, USA, 1984.
  66. T. N. Raju, “The Nobel chronicles. 1988: James Whyte Black, (b 1924), Gertrude Elion (1918–99), and George H Hitchings (1905–98),” The Lancet, vol. 355, no. 9208, p. 1022, 2000. View at Publisher · View at Google Scholar · View at Scopus
  67. A. L. Hopkins, J. S. Mason, and J. P. Overington, “Can we rationally design promiscuous drugs?” Current Opinion in Structural Biology, vol. 16, no. 1, pp. 127–136, 2006. View at Publisher · View at Google Scholar · View at Scopus
  68. I. Nobeli, A. D. Favia, and J. M. Thornton, “Protein promiscuity and its implications for biotechnology,” Nature Biotechnology, vol. 27, no. 2, pp. 157–167, 2009. View at Publisher · View at Google Scholar · View at Scopus
  69. J.-U. Peters, P. Schnider, P. Mattei, and M. Kansy, “Pharmacological promiscuity: dependence on compound properties and target specificity in a set of recent Roche compounds,” ChemMedChem, vol. 4, no. 4, pp. 680–686, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. A. Merino, A. K. Bronowska, D. B. Jackson, and D. J. Cahill, “Drug profiling: knowing where it hits,” Drug Discovery Today, vol. 15, no. 17-18, pp. 749–756, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. A. S. Reddy and S. Zhang, “Polypharmacology: drug discovery for the future,” Expert Review of Clinical Pharmacology, vol. 6, no. 1, pp. 41–47, 2013. View at Publisher · View at Google Scholar · View at Scopus
  72. Z. Simon, Á. Peragovics, M. Vigh-Smeller et al., “Drug effect prediction by polypharmacology-based interaction profiling,” Journal of Chemical Information and Modeling, vol. 52, no. 1, pp. 134–145, 2012. View at Publisher · View at Google Scholar · View at Scopus
  73. M. A. Yildirim, K.-I. Goh, M. E. Cusick, A.-L. Barabási, and M. Vidal, “Drug-target network,” Nature Biotechnology, vol. 25, no. 10, pp. 1119–1126, 2007. View at Publisher · View at Google Scholar · View at Scopus
  74. B. M. Padhy and Y. K. Gupta, “Drug repositioning: re-investigating existing drugs for new therapeutic indications,” Journal of Postgraduate Medicine, vol. 57, no. 2, pp. 153–160, 2011. View at Publisher · View at Google Scholar · View at Scopus
  75. G. Jin and S. T. C. Wong, “Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines,” Drug Discovery Today, vol. 19, no. 5, pp. 637–644, 2014. View at Publisher · View at Google Scholar · View at Scopus
  76. B. N. Armbruster and B. L. Roth, “Mining the receptorome,” The Journal of Biological Chemistry, vol. 280, no. 7, pp. 5129–5132, 2005. View at Publisher · View at Google Scholar · View at Scopus
  77. N. H. Jensen and B. L. Roth, “Massively parallel screening of the receptorome,” Combinatorial Chemistry & High Throughput Screening, vol. 11, no. 6, pp. 420–426, 2008. View at Publisher · View at Google Scholar · View at Scopus
  78. B. L. Roth, “Receptor systems: will mining the receptorome yield novel targets for pharmacotherapy?” Pharmacology & Therapeutics, vol. 108, no. 1, pp. 59–64, 2005. View at Publisher · View at Google Scholar · View at Scopus
  79. B. L. Roth and W. K. Kroeze, “Screening the receptorome yields validated molecular targets for drug discovery,” Current Pharmaceutical Design, vol. 12, no. 14, pp. 1785–1795, 2006. View at Publisher · View at Google Scholar · View at Scopus
  80. B. L. Roth, D. J. Sheffer, and W. K. Kroeze, “Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia,” Nature Reviews Drug Discovery, vol. 3, no. 4, pp. 353–359, 2004. View at Publisher · View at Google Scholar · View at Scopus
  81. R. T. Strachan, G. Ferrara, and B. L. Roth, “Screening the receptorome: an efficient approach for drug discovery and target validation,” Drug Discovery Today, vol. 11, no. 15-16, pp. 708–716, 2006. View at Publisher · View at Google Scholar · View at Scopus
  82. B. L. Roth, E. Lopez, S. Beischel, R. B. Westkaemper, and J. M. Evans, “Screening the receptorome to discover the molecular targets for plant-derived psychoactive compounds: a novel approach for CNS drug discovery,” Pharmacology & Therapeutics, vol. 102, no. 2, pp. 99–110, 2004. View at Publisher · View at Google Scholar · View at Scopus
  83. B. L. Roth, E. Lopez, S. Patel, and W. K. Kroeze, “The multiplicity of serotonin receptors: uselessly diverse molecules or an embarrassment of riches?” Neuroscientist, vol. 6, no. 4, pp. 252–262, 2000. View at Publisher · View at Google Scholar · View at Scopus
  84. J. A. Ballesteros, L. Shi, and J. A. Javitch, “Structural mimicry in G protein-coupled receptors: Implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors,” Molecular Pharmacology, vol. 60, no. 1, pp. 1–19, 2001. View at Google Scholar · View at Scopus
  85. D. A. Shapiro, K. Kristiansen, D. M. Weiner, W. K. Kroeze, and B. L. Roth, “Evidence for a model of agonist-induced activation of 5-hydroxytryptamine 2A serotonin receptors that involves the disruption of a strong ionic interaction between helices 3 and 6,” Journal of Biological Chemistry, vol. 277, no. 13, pp. 11441–11449, 2002. View at Publisher · View at Google Scholar · View at Scopus
  86. G. Fenalti, P. M. Giguere, V. Katritch et al., “Molecular control of δ-opioid receptor signalling,” Nature, vol. 506, no. 7487, pp. 191–196, 2014. View at Publisher · View at Google Scholar · View at Scopus
  87. E. Vardy, P. D. Mosier, K. J. Frankowski et al., “Chemotype-selective modes of action of κ-opioid receptor agonists,” The Journal of Biological Chemistry, vol. 288, no. 48, pp. 34470–34483, 2013. View at Publisher · View at Google Scholar · View at Scopus
  88. C. Wang, Y. Jiang, J. Ma et al., “Structural basis for molecular recognition at serotonin receptors,” Science, vol. 340, no. 6132, pp. 610–614, 2013. View at Publisher · View at Google Scholar · View at Scopus
  89. C. Wang, H. Wu, T. Evron et al., “Structural basis for Smoothened receptor modulation and chemoresistance to anticancer drugs,” Nature Communications, vol. 5, article 4355, 2014. View at Publisher · View at Google Scholar · View at Scopus
  90. C. Wang, H. Wu, V. Katritch et al., “Structure of the human smoothened receptor bound to an antitumour agent,” Nature, vol. 497, no. 7449, pp. 338–343, 2013. View at Publisher · View at Google Scholar · View at Scopus
  91. H. Wu, D. Wacker, M. Mileni et al., “Structure of the human κ-opioid receptor in complex with JDTic,” Nature, vol. 485, no. 7398, pp. 327–332, 2012. View at Publisher · View at Google Scholar
  92. J. D. Hutcheson, V. Setola, B. L. Roth, and W. D. Merryman, “Serotonin receptors and heart valve disease—it was meant 2B,” Pharmacology & Therapeutics, vol. 132, no. 2, pp. 146–157, 2011. View at Publisher · View at Google Scholar · View at Scopus
  93. R. B. Rothman, M. H. Baumann, J. E. Savage et al., “Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications,” Circulation, vol. 102, no. 23, pp. 2836–2841, 2000. View at Publisher · View at Google Scholar · View at Scopus
  94. V. Setola, S. J. Hufeisen, K. J. Grande-Allen et al., “3,4-Methylenedioxymethamphetamine (MDMA, ‘Ecstasy’) induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro,” Molecular Pharmacology, vol. 63, no. 6, pp. 1223–1229, 2003. View at Publisher · View at Google Scholar · View at Scopus
  95. V. Setola and B. L. Roth, “Screening the receptorome reveals molecular targets responsible for drug-induced side effects: focus on ‘fen-phen’,” Expert Opinion on Drug Metabolism & Toxicology, vol. 1, no. 3, pp. 377–387, 2005. View at Publisher · View at Google Scholar · View at Scopus
  96. W. K. Kroeze, S. J. Hufeisen, B. A. Popadak et al., “H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs,” Neuropsychopharmacology, vol. 28, no. 3, pp. 519–526, 2003. View at Publisher · View at Google Scholar · View at Scopus
  97. B. L. Roth, K. Baner, R. Westkaemper et al., “Salvinorin A: a potent naturally occurring nonnitrogenous κ opioid selective agonist,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 18, pp. 11934–11939, 2002. View at Publisher · View at Google Scholar · View at Scopus
  98. Z. Feng, L. Chen, H. Maddula et al., “Ligand Depot: a data warehouse for ligands bound to macromolecules,” Bioinformatics, vol. 20, no. 13, pp. 2153–2155, 2004. View at Publisher · View at Google Scholar · View at Scopus
  99. J. J. Irwin and B. K. Shoichet, “ZINC—a free database of commercially available compounds for virtual screening,” Journal of Chemical Information and Modeling, vol. 45, no. 1, pp. 177–182, 2005. View at Publisher · View at Google Scholar · View at Scopus
  100. M. Kanehisa, S. Goto, Y. Sato, M. Furumichi, and M. Tanabe, “KEGG for integration and interpretation of large-scale molecular data sets,” Nucleic Acids Research, vol. 40, no. 1, pp. D109–D114, 2012. View at Publisher · View at Google Scholar · View at Scopus
  101. Y. Wang, J. Xiao, T. O. Suzek et al., “PubChem's BioAssay database,” Nucleic Acids Research, vol. 40, no. 1, pp. D400–D412, 2012. View at Publisher · View at Google Scholar · View at Scopus
  102. D. L. Wheeler, T. Barrett, D. A. Benson et al., “Database resources of the National Center for Biotechnology Information,” Nucleic Acids Research, vol. 36, no. 1, pp. D13–D21, 2008. View at Publisher · View at Google Scholar · View at Scopus
  103. Y. Pouliot, A. P. Chiang, and A. J. Butte, “Predicting adverse drug reactions using publicly available PubChem BioAssay data,” Clinical Pharmacology and Therapeutics, vol. 90, no. 1, pp. 90–99, 2011. View at Publisher · View at Google Scholar · View at Scopus
  104. M. J. Keiser, B. L. Roth, B. N. Armbruster, P. Ernsberger, J. J. Irwin, and B. K. Shoichet, “Relating protein pharmacology by ligand chemistry,” Nature Biotechnology, vol. 25, no. 2, pp. 197–206, 2007. View at Publisher · View at Google Scholar · View at Scopus
  105. M. J. Keiser, V. Setola, J. J. Irwin et al., “Predicting new molecular targets for known drugs,” Nature, vol. 462, no. 7270, pp. 175–181, 2009. View at Publisher · View at Google Scholar · View at Scopus
  106. E. Lounkine, M. J. Keiser, S. Whitebread et al., “Large-scale prediction and testing of drug activity on side-effect targets,” Nature, vol. 486, no. 7403, pp. 361–367, 2012. View at Publisher · View at Google Scholar · View at Scopus
  107. A.-L. Barabási and Z. N. Oltvai, “Network biology: understanding the cell's functional organization,” Nature Reviews Genetics, vol. 5, no. 2, pp. 101–113, 2004. View at Publisher · View at Google Scholar · View at Scopus
  108. M. Campillos, M. Kuhn, A.-C. Gavin, L. J. Jensen, and P. Bork, “Drug target identification using side-effect similarity,” Science, vol. 321, no. 5886, pp. 263–266, 2008. View at Publisher · View at Google Scholar · View at Scopus
  109. J. K. Morrow, L. Tian, and S. Zhang, “Molecular networks in drug discovery,” Critical Reviews in Biomedical Engineering, vol. 38, no. 2, pp. 143–156, 2010. View at Publisher · View at Google Scholar · View at Scopus
  110. L. Tian and S. Zhang, “Mapping drug-target interaction networks,” in Proceedings of the Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC '09), pp. 2336–2339, IEEE, Minneapolis, Minn, USA, September 2009. View at Publisher · View at Google Scholar
  111. A. P. Davis, B. L. King, S. Mockus et al., “The comparative toxicogenomics database: update 2011,” Nucleic Acids Research, vol. 39, no. 1, pp. D1067–D1072, 2011. View at Publisher · View at Google Scholar · View at Scopus
  112. T. I. Oprea and J. Mestres, “Drug repurposing: far beyond new targets for old drugs,” The AAPS Journal, vol. 14, no. 4, pp. 759–763, 2012. View at Publisher · View at Google Scholar · View at Scopus
  113. T. I. Oprea, S. Kim Nielsen, O. Ursu et al., “Associating drugs, targets and clinical outcomes into an integrated network affords a new platform for computer-aided drug repurposing,” Molecular Informatics, vol. 30, no. 2-3, pp. 100–111, 2011. View at Publisher · View at Google Scholar · View at Scopus
  114. F. Cheng, Y. Zhou, W. Li, G. Liu, and Y. Tang, “Prediction of chemical-protein interactions network with weighted network-based inference method,” PLoS ONE, vol. 7, no. 7, Article ID e41064, 2012. View at Publisher · View at Google Scholar · View at Scopus
  115. D. Reker, T. Rodrigues, P. Schneider, and G. Schneider, “Identifying the macromolecular targets of de novo-designed chemical entities through self-organizing map consensus,” Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 11, pp. 4067–4072, 2014. View at Publisher · View at Google Scholar · View at Scopus
  116. C. A. Erickson, J. M. Veenstra-Vanderweele, R. D. Melmed et al., “STX209 (arbaclofen) for autism spectrum disorders: an 8-week open-label study,” Journal of Autism and Developmental Disorders, vol. 44, no. 4, pp. 958–964, 2014. View at Publisher · View at Google Scholar · View at Scopus
  117. J. R. Morphy and C. J. Harris, Designing Multi-Target Drugs, Royal Society of Chemistry, London, UK, 2012.
  118. B. Apsel, J. A. Blair, B. Gonzalez et al., “Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases,” Nature Chemical Biology, vol. 4, no. 11, pp. 691–699, 2008. View at Publisher · View at Google Scholar · View at Scopus
  119. J. Besnard, G. F. Ruda, V. Setola et al., “Automated design of ligands to polypharmacological profiles,” Nature, vol. 492, no. 7428, pp. 215–220, 2012. View at Publisher · View at Google Scholar · View at Scopus
  120. K. D. McLaren and L. B. Marangell, “Special considerations in the treatment of patients with bipolar disorder and medical co-morbidities,” Annals of General Hospital Psychiatry, vol. 3, no. 1, article 7, 2004. View at Publisher · View at Google Scholar · View at Scopus
  121. E. M. Berry-Kravis, D. Hessl, B. Rathmell et al., “Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial,” Science Translational Medicine, vol. 4, no. 152, Article ID 152ra127, 2012. View at Publisher · View at Google Scholar · View at Scopus
  122. A. Healy, R. Rush, and T. Ocain, “Fragile X syndrome: an update on developing treatment modalities,” ACS Chemical Neuroscience, vol. 2, no. 8, pp. 402–410, 2011. View at Publisher · View at Google Scholar · View at Scopus
  123. R. Lozano, E. B. Hare, and R. J. Hagerman, “Modulation of the GABAergic pathway for the treatment of fragile X syndrome,” Neuropsychiatric Disease and Treatment, vol. 10, pp. 1769–1779, 2014. View at Publisher · View at Google Scholar · View at Scopus
  124. M. R. Mohammadi, L. Kashani, S. Akhondzadeh, E. S. Izadian, and S. Ohadinia, “Efficacy of theophylline compared to methylphenidate for the treatment of attention-deficit hyperactivity disorder in children and adolescents: a pilot double-blind randomized trial,” Journal of Clinical Pharmacy and Therapeutics, vol. 29, no. 2, pp. 139–144, 2004. View at Publisher · View at Google Scholar · View at Scopus
  125. H. J. Moller, K. Demyttenaere, B. Olausson et al., “Two phase III randomised double-blind studies of fixed-dose TC-5214 (dexmecamylamine) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to prior antidepressant therapy,” The World Journal of Biological Psychiatry, vol. 16, no. 7, pp. 483–501, 2015. View at Google Scholar
  126. E. Vieta, M. E. Thase, D. Naber et al., “Efficacy and tolerability of flexibly-dosed adjunct TC-5214 (dexmecamylamine) in patients with major depressive disorder and inadequate response to prior antidepressant,” European Neuropsychopharmacology, vol. 24, no. 4, pp. 564–574, 2014. View at Publisher · View at Google Scholar · View at Scopus
  127. A. Corbett, J. Smith, and C. Ballard, “New and emerging treatments for Alzheimers disease,” Expert Review of Neurotherapeutics, vol. 12, no. 5, pp. 535–543, 2012. View at Publisher · View at Google Scholar · View at Scopus
  128. T. P. George, K. A. Sacco, J. C. Vessicchio, A. H. Weinberger, and R. D. Shytle, “Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor-refractory major depressive disorder: a preliminary study,” Journal of Clinical Psychopharmacology, vol. 28, no. 3, pp. 340–344, 2008. View at Publisher · View at Google Scholar · View at Scopus
  129. E. D. Levin and B. B. Simon, “Nicotinic acetylcholine involvement in cognitive function in animals,” Psychopharmacology, vol. 138, no. 3-4, pp. 217–230, 1998. View at Publisher · View at Google Scholar · View at Scopus
  130. A. Singh, D. K. Das, and M. E. Kelley, “Mecamylamine: Targacept,” IDrugs, vol. 9, no. 3, pp. 205–217, 2006. View at Google Scholar · View at Scopus
  131. K.-I. Ueno, H. Togashi, M. Matsumoto, S. Ohashi, H. Saito, and M. Yoshioka, “α4β2 Nicotinic acetylcholine receptor activation ameliorates impairment of spontaneous alternation behavior in stroke-prone spontaneously hypertensive rats, an animal model of attention deficit hyperactivity disorder,” The Journal of Pharmacology and Experimental Therapeutics, vol. 302, no. 1, pp. 95–100, 2002. View at Publisher · View at Google Scholar · View at Scopus
  132. J. K. Belanoff, B. H. Flores, M. Kalezhan, B. Sund, and A. F. Schatzberg, “Rapid reversal of psychotic depression using mifepristone,” Journal of Clinical Psychopharmacology, vol. 21, no. 5, pp. 516–521, 2001. View at Publisher · View at Google Scholar · View at Scopus
  133. C. M. Blasey, T. S. Block, J. K. Belanoff, and R. L. Roe, “Efficacy and safety of mifepristone for the treatment of psychotic depression,” Journal of Clinical Psychopharmacology, vol. 31, no. 4, pp. 436–440, 2011. View at Publisher · View at Google Scholar · View at Scopus
  134. B. J. Carroll and R. T. Rubin, “Mifepristone in psychotic depression?” Biological Psychiatry, vol. 63, no. 1, pp. e1–e3, 2008. View at Google Scholar
  135. R. H. Howland, “Mifepristone as a therapeutic agent in psychiatry,” Journal of Psychosocial Nursing and Mental Health Services, vol. 51, no. 6, pp. 11–14, 2013. View at Publisher · View at Google Scholar · View at Scopus
  136. C. E. Clarke and K. H. Deane, “Ropinirole for levodopa-induced complications in Parkinson's disease,” The Cochrane Database of Systematic Reviews, vol. 3, Article ID CD001516, 2000. View at Google Scholar · View at Scopus
  137. C. E. Clarke and K. H. Deane, “Ropinirole for levodopa-induced complications in Parkinson's disease,” The Cochrane Database of Systematic Reviews, no. 1, Article ID CD001516, 2001. View at Google Scholar · View at Scopus
  138. R. Tomasiuk, S. Szlufik, A. Friedman, and D. Koziorowski, “Ropinirole treatment in Parkinson's disease associated with higher serum level of inflammatory biomarker NT-proCNP,” Neuroscience Letters, vol. 566, pp. 147–150, 2014. View at Publisher · View at Google Scholar · View at Scopus
  139. A. Yildiz, S. Guleryuz, D. P. Ankerst, D. Öngür, and P. F. Renshaw, “Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen,” Archives of General Psychiatry, vol. 65, no. 3, pp. 255–263, 2008. View at Publisher · View at Google Scholar · View at Scopus
  140. A. Corbett, G. Williams, and C. Ballard, “Drug repositioning: an opportunity to develop novel treatments for Alzheimer's disease,” Pharmaceuticals, vol. 6, no. 10, pp. 1304–1321, 2013. View at Publisher · View at Google Scholar · View at Scopus